Higher levels of IL‐6 early after tocilizumab distinguish survivors from nonsurvivors in COVID‐19 pneumonia: A possible indication for deeper targeting of IL‐6

INTRODUCTION: The most serious COVID‐19 deriving from severe acute respiratory syndrome coronavirus 2 causes a cytokine release storm and it is associated with worse outcomes. In COVID‐19 patients, interleukin‐6 (IL‐6) levels are significantly elevated. Blocking IL‐6 preliminarily resulted in the im...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Med Virol
Main Authors: Quartuccio, Luca, Sonaglia, Arianna, Pecori, Davide, Peghin, Maddalena, Fabris, Martina, Tascini, Carlo, De Vita, Salvatore
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Short Communications
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7301025/
https://ncbi.nlm.nih.gov/pubmed/32515499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jmv.26149
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados